Puma Biotech Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3–7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.